Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.7% – Here’s Why

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares traded down 3.7% on Thursday . The company traded as low as $0.32 and last traded at $0.35. 51,497,243 shares traded hands during mid-day trading, an increase of 103% from the average session volume of 25,332,580 shares. The stock had previously closed at $0.36.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research note on Sunday. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Trading Up 39.7 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm’s fifty day moving average is $0.18 and its two-hundred day moving average is $0.52. The firm has a market capitalization of $95.28 million, a PE ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. On average, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.